Healthcare: Lessons from the pandemic & how to prepare for the future

Every adversity sows the seed of opportunity but whether it is leveraged depends on how the experiences are moulded to face the next challenge. Nowhere is this more relevant than in the healthcare sector, which is bang in the middle of the ongoing coronavirus pandemic.

While the spread of the virus has brought the global economy down to its knees, it has also reminded everyone that different spokes of the healthcare sector must work together. Be it diagnosis (read pathology), basic and emergency protection (read PPE kits and medical devices like ventilators) or treatment (drug research, medicines and hospitals), all the sub-segments of the industry need to function without disruption.

Not surprisingly, healthcare has stood out in attracting private investments. The first nine months of this year have already surpassed the $1-1.5 billion worth of private equity and venture capital money that the industry has been pulling in every year, according to data collated by VCCEdge.

If the current trends continue, the healthcare sector may also buck the broader trend where the number of companies attracting capital has declined, to at least match—if not improve—the tally of previous years where, on average, two healthcare firms were getting funded every week.

The pandemic has also shown the inadequacies of public and private healthcare delivery ecosystems. The diagnostics infrastructure took months to reach an optimal level to test infected patients. The hospital infrastructure faces a serious shortage of beds to cater to even those who are ready to pay a marked-up charge. Most critically, the process of drug and vaccine development is far from satisfactory. Some programmes that intersect in the public-private domain in India, like the government’s Ayushman Bharat health insurance scheme, have been moving in the right direction. The number of patients under the scheme has doubled in its second year and half a million people have reportedly availed its benefits for Covid-19 alone.

But we are running behind in creating a national health stack and a national health register to maintain digitised records of citizens. Once in motion it could complement the decades-old, low-cost healthcare delivery systems like telemedicine, which got a leg-up in the last few months, for more effective and faster impact.

Overall, the pandemic has proven that both public and private institutions must invest more in the healthcare industry, and effectively use technology to face such a shock in the future. It has also shown the need for swifter business decisions with respect to product planning (devices); development of low-cost diagnostics processes; efficient hospital infrastructure utilisation without usurious charges that feed distrust; and more research for drug and vaccine development to tackle newer strains of viral and bacterial diseases.

To discuss the experiences of various stakeholders and learn the lessons to face challenges of the future, VCCircle is organising the 12th edition of the Healthcare Investment Summit on December 11, 2020 on a virtual platform.


9:00 AM onwards
  • 9:00 AM – 9:30 AM


  • 9:30 AM – 9:40 AM

    Opening Address

  • 9:40 AM – 10:00 AM

    Keynote Address

    Lessons on public private partnership in dealing with pandemic

  • 10:00 AM – 10:30 AM

    Panel Discussion 1: Learnings from systemic shock

    Pathology chains, hospitals, medical device makers, health insurers and drugmakers, especially vaccine developers, and drug research firms faced numerous challenges. And they continue to feel the stress over the public demand for a swifter and more effective response to the pandemic. What lessons can help handle such a situation in the future?


  • 10:30 AM – 10:40 AM

    QnA Session

  • 10:40 AM – 11:10 AM

    Panel Discussion 2: Hospitals go omni-channel; need to tap into home healthcare, telemedicine?

    Hospitals faced an unprecedented decline in occupancy levels as non-Covid patients postponed treatment. They also faced a Catch-22 situation as demand for telemedicine, which was traditionally seen as a means to reach the underserved population in the hinterland, spiked and they faced a pricing problem in the cities.

    Can hospitals manage demand for beds with more telemedicine while keeping pricing at a level that’s acceptable to patients and enough to manage their own infrastructure? Can home healthcare tie-ups form the middle ground?

  • 11:10 AM – 11:20 AM

    QnA Session

  • 11:20 AM – 11:50 AM

    Panel Discussion 3: Drug discovery and development

    Companies have tried to repurpose older drugs to treat COVID-19, even as the search for a vaccine continues globally. India is likely to also emerge as the manufacturing hub for the COVID-19 vaccine. Can the pandemic give a boost to innovative drug discovery research in India? How can the government and the drug regulator step in to monitor safe scientific research and for clinical trials while also fostering an environment for innovation?

  • 11:50 AM – 12:00 PM

    QnA Session

  • 12:00 PM – 12:30 PM

    Panel Discussion 4: Health-tech arrives and how

    The two most heavily funded sub-segments of the health-tech space – e-pharmacy and online doctor consultation – got a huge fillip during the lockdown. The pandemic has also revived the interest of early-stage investors in health-tech. While consolidation is afoot in e-pharmacy, other health-tech segments need to see if the spike in monetisation and run rate can be sustained. Will this be the beginning of Health-tech 2.0 in India?


  • 12:30 PM – 12:40 PM

    QnA Session

  • 12:40 PM – Onwards

    End of Conference

Speakers 2020


Sudarshan Jain

Secretary General, Indian Pharmaceutical Alliance

Pavan Choudary

Chairman and Director General, Medical Technology Association of India

Dr. K Ganapathy

Director, Apollo Telemedicine Networking Foundation

Vivek Tiwari

CEO, Medikabazaar

Mayank Bathwal

CEO, Aditya Birla Health Insurance

Vivek Srivastava

Co-founder & CEO, HealthCare atHOME India

Prashant Singh

Director & CIO, Max Healthcare

Want to be part of it?

VCC Events opens up the avenues for participation. Join hands to be a part of India’s largest gathering of alternative investments leaders, industry stakeholders and Asia’s influential limited partners, general partners and marquee advisors. Your chance to actively participate and augment yourself as thought leaders.


Individual Ticket

For any query, please reach us at, +91-9560888566 / +91-120-4171111

Cancellation Policy:

There is no cash refund in case you cancel the registration from your end. We will issue a credit note for an equivalent amount which you can adjust/utilise against any of our future events (under the validity period) if the registration is cancelled at least 3 days before the event, post which NO credit note will be issued. Company reserves the right to amend content, expert, policy, venue & date(s) of the conference. Delegates will be refunded the registration fee in full in case the conference gets cancelled from our end.

Substitution Policy:

Substitutions within a company are permitted through the conference date. Shared registrations are not permitted under any circumstances.

Do you have any queries?

Drop us a line and we will call you.